SCHEMBL2174388

SCHEMBL2174388

CC(C)(C)OC(=O)NN1CCC(OCc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TMEM97 Q5BJF2 1/20 0.44
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
PRMT8 Q9NR22 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
BCHE P06276 4/20 0.42
CTSL P07711 1/20 0.42
ABCB1 P08183 1/20 0.41
AGTR2 P50052 2/20 0.41
KLK7 P49862 3/20 0.41
KLK5 Q9Y337 1/20 0.41
NAAA Q02083 2/20 0.40
STS P08842 1/20 0.40
MMP2 P08253 1/20 0.40
MMP13 P45452 1/20 0.40
SYK P43405 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4228422 0.80 ACACB (0.48) MMP13
SCHEMBL942191 0.80 JAK2 (0.55) BCHEKLK7STS
SCHEMBL20503925 0.80 JAK2 (0.55) BCHEKLK7STS
SCHEMBL697850 0.80 JAK2 (0.55) BCHEKLK7STS
SCHEMBL28256693 0.79 KMT2A (0.43) KMT2AL3MBTL1SIGMAR1CTSLSTS
SCHEMBL28792068 0.79 KMT2A (0.43) KMT2AL3MBTL1SIGMAR1CTSLSTS
SCHEMBL606732 0.79 CTSL (0.52) KMT2AL3MBTL1CTSLSTSSYK
SCHEMBL7479137 0.79 PPARA (0.45) KMT2AL3MBTL1CTSL
SCHEMBL7486941 0.77 USP30 (0.47) CARM1PRMT6
SCHEMBL3249107 0.77 STS (0.58) STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247578-B2 Process for production of aralkyloxypyrrolidine derivative KANEKA CORPORATION (JP) 2012-08-21 US disclosed
US-20110224444-A1 PROCESS FOR PRODUCTION OF ARALKYLOXYPYRROLIDINE DERIVATIVE KANEKA CORPORATION (JP) 2011-09-15 US disclosed
US-7973176-B2 Process for production of aralkyloxypyrrolidine derivative KANEKA CORPORATION (JP) 2011-07-05 US disclosed
EP-1947083-B1 PROCESS FOR PRODUCTION OF ARALKYLOXYPYRROLIDINE DERIVATIVE KANEKA CORP (JP) 2010-11-10 EP disclosed
US-20080306283-A1 Process For Production of Aralkyloxypyrrolidine Derivative KANEKA CORPORATION (JP) 2008-12-11 US disclosed
EP-1947083-A1 PROCESS FOR PRODUCTION OF ARALKYLOXYPYRROLIDINE DERIVATIVE Kaneka Corporation (JP) 2008-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306283-A1 Process For Production of Aralkyloxypyrrolidine Derivative HPD, HAAO, ARL1 KMT2A 2745/4885L3MBTL1 3608/4885TMEM97 3899/4885
US-20110224444-A1 PROCESS FOR PRODUCTION OF ARALKYLOXYPYRROLIDINE DERIVATIVE HPD, HAAO, ARL1 KMT2A 2745/4885L3MBTL1 3608/4885TMEM97 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.